NCT06352528 2025-10-06
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Bristol-Myers Squibb
Phase 1 Completed
Clinical Trials
4 trialsNCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT04772235 2024-04-03
TOTEM
Instituto Oncológico Dr Rosell
Phase 1 Recruiting
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn